clinical trial · NCT06712472
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
Gustave Roussy, Cancer Campus, Grand Paris·phase3·recruiting·n = 554
Endometrial Cancerp53abnOlaparib (300 mg BID)
brief summary
The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.
started
Jun 26, 2024
primary completion
Jun 1, 2030
completion
Dec 1, 2031
last updated
Jan 20, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol